Ginkgo Bioworks' Big Team-Up Ginkgo Bioworks: Bad News and Worse News Consequently, if the company continues to run afoul of the NYSE's listing rules, don't be too surprised if the exchange delists Ginkgo Bioworks. Getting kicked off the prestigious NYSE and relegated to the over-thecounter gulag would be a harsh blow for Ginkgo Bioworks and its loyal shareholders. There's definitely a science to picking beaten-down gems in the stock market. If you get it wrong, you could lose a lot of money. Ginkgo Biowork ...

Ginkgo Bioworks (NYSE:DNA) layoffs continue today with the cell programming company announcing additional job cuts. Ginkgo Bioworks notes that these layoffs are part of a restructuring plan. This will see some of the job cuts happening in 2025 as it continues to alter its business. However, the initial job cuts will begin this month. More Ginkgo Bioworks Layoffs DNA stock is down 10.6% as of Wednesday afternoon. That comes with over 52 million shares traded. This is above its daily average trading volume of ...

Core Viewpoint - QIAGEN has launched 35 new wet-lab tested digital PCR Microbial DNA Detection Assays for its QIAcuity platform, enhancing its capabilities in microbial research and solidifying its leadership in microbial detection and analysis [1][2][3] Product Expansion - The new assays target critical pathogens including Dengue virus Serotypes 1 to 4, Monkeypox clades I and II, and Chikungunya, among others, increasing QIAGEN's total microbial dPCR assay portfolio to over 680 targets [2] - The expansion is part of a broader plan to enhance QIAGEN's wet-lab-tested dPCR assay portfolio, with at least 100 additional dPCR assays expected to be launched throughout 2024 [2] Technological Advancements - QIAGEN's QIAcuity platform utilizes nanoplates to partition samples into thousands of tiny sections, allowing for simultaneous reading of reactions, which enhances sensitivity and specificity in detecting DNA and RNA [4] - The platform reduces processing times from six hours to just two, accommodating various laboratory sizes and throughput requirements [4] Public Health Impact - The new assays are positioned as a timely response to public health crises, enabling precise detection of pathogens and facilitating prompt intervention measures, which can improve patient outcomes [3] Conference Participation - QIAGEN will showcase its expanded digital PCR offerings at the ASM Microbe conference from June 13–17 in Atlanta, Georgia, providing attendees with insights into its microbial research and diagnostic capabilities [5] Research Contributions - QIAGEN will present research on improved extraction methods for total nucleic acid from microbiome samples, emphasizing the importance of mechanical lysis for efficient extraction [6] Collaborative Efforts - A spotlight session on June 16 will highlight QIAGEN's collaboration with the Water Tower Institute and the Public Health Lab Tennessee, focusing on Legionella monitoring using the QIAcuity platform [7]

Morgan Stanley recently released its bullish take on the biotech space, driven by anticipated interest rate cuts and a surge in mergers and acquisitions (M&A) activity. The analyst firm states biotech stocks typically outshine the market just before a rate cut. Moreover, increased optimism spurs an uptick in M&A activity, contributing to a more active biotech sector. Hence, discarding underperforming biotech stocks to sell is imperative, as the industry is picking up steam again. Rallybio (RLYB) Source: Shu ...

This innovative biotechnology company hopes to turn things around. Once upon a time, Ginkgo Bioworks (DNA -0.25%) was viewed by many as a rising star in the biotechnology world. However, since its initial public offering in September 2021, the stock has plunged 95%. So far in 2024, Ginkgo's shares have fallen more than 60%. Can Ginkgo Bioworks stage a major comeback? Or is the stock likely to continue floundering? Two Motley Fool contributors make the bull and bear arguments for Ginkgo. Bull case: A growing ...

Core Viewpoint - Ginkgo Bioworks has experienced a significant decline in share price, dropping 50% in the last three months, which may present a buying opportunity for investors if future recovery is anticipated [1][2] Financial Performance - In Q1, Ginkgo reported a revenue of $28 million from its biofoundry segment, an 18% decrease year-over-year, indicating ongoing unprofitability despite adding 17 new cell engineering programs [3] - Management has initiated a cost-cutting program aimed at reducing expenses by $200 million annually, with a target completion before mid-next year [4] Cost Management and Profitability Outlook - The cost-cutting plan includes a 25% reduction in labor costs, likely resulting in layoffs, particularly in R&D, and a potential 60% reduction in foundry lab space [4] - If cost reductions are successful, adjusted EBITDA is expected to reach breakeven by the end of 2026, although a positive net profit margin under GAAP is not anticipated at that time [6] Revenue Projections - For 2024, Ginkgo anticipates revenue from cell engineering services to be up to $140 million, impacted by slower revenue growth from existing programs and cost-cutting measures [7] - The company has shifted its focus away from the number of new programs onboarded as a key metric, which may indicate a slowdown in growth [8] Cash Position and Financial Risks - As of the end of Q1, Ginkgo held $840 million in cash and equivalents, with trailing-12-month operating expenses of $898.3 million, suggesting potential cash flow challenges despite cost-cutting efforts [10] - The company has no long-term debt but does have $221.8 million in long-term capital lease obligations, indicating possible avenues for raising cash through borrowing or stock issuance [11] Future Potential - There is a scenario where Ginkgo could become a profitable provider of biotech services, but a clear trajectory toward this goal is necessary for the stock to be attractive to investors [13]

Venlo, the Netherlands, May 29, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of its QIAseq Multimodal DNA/RNA Lib Kit. The new kit enables seamless preparation of DNA and RNA libraries for next-generation sequencing (NGS), such as whole genome sequencing (WGS) and whole transcriptome sequencing (WTS), as well as downstream target enrichment based on hybrid-capture from a single sample. The QIAseq Multimodal DNA/RNA Lib Kit facilitates multiomics, the ...

You don't need to buy her picks, but it's worth understanding them. Cathie Wood's commitment to buying shares of businesses working on disruptive innovations, via her ARK Innovation ETF and ARK Genomic Revolution ETF, makes her investing style very much on the riskier side of the spectrum -- especially when she invests in already risky areas like biotech. But if her theses are correct, the upside to investors could be tremendous, assuming they can tolerate what might be a very long and bumpy ride between bu ...

Core Insights - Ginkgo Bioworks aims to become a leading biotech partner in the biopharma sector through low-cost bioengineering and biomanufacturing services, but it currently faces significant challenges [1][2] Group 1: Biofoundry and Automation - Ginkgo's biofoundry provides a platform for biotech and pharma companies to design and cultivate microorganisms at scale, generating desired outputs like biomolecules [3] - The company utilizes custom-built laboratory automation hardware, specifically reconfigurable-automation carts (RACs), to create a highly automated and customized workflow [5][6] - The efficiency of RACs compared to traditional high-throughput solutions is a critical factor for the company's operational success [7][8] Group 2: Financial Health - As of the first quarter, Ginkgo had $840 million in cash and cash equivalents, with operating expenses of $215.9 million, leading to a net cash decrease of $102.3 million [9] - The company has initiated a cost-cutting campaign aimed at reducing expenses by approximately $200 million annually, including a 25% reduction in personnel costs [10][11] Group 3: Stock Performance and Delisting Risk - Ginkgo's stock has declined by 42% over the past year, with a current share price of around $0.74, below the $1 minimum bid price required by the New York Stock Exchange [12][13] - The company has been warned about potential delisting and has six months to regain compliance, with options such as a reverse-share split or announcing new initiatives to boost share price [13][14]

Reasons to buy Ginkgo Bioworks The company's cell engineering platform combines robotics and artificial intelligence (AI) to produce new cell lines for its clients. This is important because many top-selling drugs are manufactured by genetically modified cells that produce a specific protein. Disrupting the biopharmaceutical manufacturing industry could be extremely lucrative and it isn't the only way Ginkgo's cell engineering platform can earn money. For example, it recently partnered with plant-biotech co ...